Filing Flows › X4 Pharmaceuticals (XFOR) › Q2 2026 › vs Q2 2025
X4 Pharmaceuticals (XFOR) Q2 2026 vs Q2 2025 (year over year)
X4 Pharmaceuticals's revenue rose $700K (+41%) from $1.7M in Q2 2025 to $2.4M in Q2 2026. The biggest changes: Revenue from contracts with customers +$6.8M (+346%).
X4 Pharmaceuticals, Q2 2026: revenue $2.4M (+41% year over year), operating margin -683.0%, net loss $16.2M, operating cash flow −$20.8M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| License and other revenue | $6.4M | $229K | $6.2M | 28× |
| Product revenue, net | $2.4M | $1.7M | $629K | +36% |
| Revenue from contracts with customers | $8.8M | $2.0M | $6.8M | +346% |
| Revenue | $2.4M | $1.7M | $700K | +41% |
| Other revenues (net loss) | $6.4M | $273K | $6.1M | 23× |
| Other income, net | $236K | $528K | −$292K | -55% |
| Net loss | $16.2M | $25.7M | −$9.6M | -37% |
| Costs & expenses | $18.8M | $28.0M | −$9.2M | -33% |
| Operating costs | $18.8M | $27.9M | −$9.1M | -33% |
| Income tax | $2K | $37K | −$35K | -95% |
| Operating cash sources | $24.9M | $31.0M | −$6.1M | -20% |
| Depreciation & amortization | $997K | $355K | $642K | +181% |
| Share-based compensation | $3.1M | $748K | $2.3M | +313% |
| Cash used in operations | $20.8M | $29.9M | −$9.1M | -30% |
| Net loss absorbed | $16.2M | $25.7M | −$9.6M | -37% |
| Working capital & other | $8.7M | $5.3M | $3.5M | +66% |
Questions
How much did X4 Pharmaceuticals's revenue grow year over year in Q2 2026?
X4 Pharmaceuticals's revenue rose $700K (+41%) from $1.7M in Q2 2025 to $2.4M in Q2 2026.
What drove X4 Pharmaceuticals's revenue change in Q2 2026?
Revenue from contracts with customers +$6.8M (+346%).